If your personal data are processed based on your consent, you may withdraw your consent to personal data processing at any time, whereas this will not affect lawfulness of prior processing.

Preparat zawiera wyciągi roślinne iwitaminy. 1tabletka zawiera: 50 mg izoflawonów znasion soi, 30 mg wyciągu zszyszek chmielu, 10 mg wyciągu znasion lnu, 400 mg wapnia, 5µg witaminy D3, 1,4 mg witaminy B6, 12 mg witaminy E, 0,2 mg kwasu foliowego. Increased plasma high-density lipoprotein (HDL) and HDL 2 cholesterol subfraction concentrations, reduced low-density lipoprotein (LDL) cholesterol concentration, and increased triglyceride levels. Should any adhesive remain on the skin after removal of the Climara Forte system, allow the area to dry for 15 minutes. Then gently rubbing the area with an oil-based cream or lotion should remove the adhesive residue. In the WHI estrogen-alone substudy, the risk of VTE (DVT and PE) was increased for women receiving daily CE (0.625 mg)-alone compared to placebo (30 versus 22 per 10,000 women-years), although only the increased risk of DVT reached statistical significance (23 versus 15 per 10,000 women-years). The increase in VTE risk was demonstrated during the first 2 years 3. Should a VTE occur or be suspected, estrogen-alone therapy should be discontinued immediately. Hsia J, et al. Conjugated Equine Estrogens and Coronary Heart Disease. Arch Int Med. 2006;166:357-365.Accelerated prothrombin time, partial thromboplastin time, and platelet aggregation time; increased platelet count; increased factors II, VII antigen, VIII antigen, VIII coagulant activity, IX, X, XII, VII-X complex, II-VII-X complex, and beta-thromboglobulin; decreased levels of antifactor Xa and antithrombin III, decreased antithrombin III activity; increased levels of fibrinogen and fibrinogen activity; increased plasminogen antigen and activity. Climea Forte, a special supplement that affects the well-being and alleviate the discomfort of women, associated with menopause. The composition of the preparation is a double dose of soy isoflavones, which are classified as phytoestrogens - or plant counterparts of female hormones. Soy isoflavones are safe and have a mild effect on the endocrine women - without causing side effects. Due to the increased content of calcium and vitamin D3 Climea forte, also it allows you to maintain the proper structure and bone density. Enriched with the preparation that improves the appearance of the skin, and also relieves symptoms of fatigue and irritability associated with the menopause.

The following adverse reactions have been identified during post-approval use of the Climara Forte transdermal system. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Genitourinary System The most important randomized clinical trial providing information about breast cancer in estrogen-alone users is the WHI substudy of daily CE (0.625 mg)-alone. In the WHI estrogen-alone substudy, after an average follow-up of 7.1 years, daily CE-alone was not associated with an increased risk of invasive breast cancer [relative risk (RR) 0.80] 5. Long-term continuous administration of natural and synthetic estrogens in certain animal species increases the frequency of carcinomas of the breast, uterus, cervix, vagina, testis, and liver. Use In Specific Populations PregnancyIn the WHIMS estrogen plus progestin ancillary study, a population of 4,532 postmenopausal women 65 to 79 years of age was randomized to daily CE (0.625 mg) plus MPA (2.5 mg) or placebo. After an average follow-up of 4 years, 40 women in the CE plus MPA group and 21 women in the placebo group were diagnosed with probable dementia. The relative risk of probable dementia for CE plus MPA versus placebo was 2.05 (95 percent CI, 1.21-3.48). The absolute risk of probable dementia for CE plus MPA versus placebo was 45 versus 22 cases per 10,000 women-years 8. Dose proportionality was demonstrated for the Climara Forte 6.5 cm² transdermal system as compared to the Climara Forte 12.5 cm² transdermal system in a 2-week crossover study with a 1-week washout period between the two-transdermal systems in 24 postmenopausal women.